Guidelines Archive

Friday, April 29, 2022

• Full Guideline

Friday, April 8, 2022

• Full Guideline

Friday, April 1, 2022

• Full Guideline

Thursday, March 24, 2022

• Full Guideline
• Statement on Bebtelovimab

Wednesday, March 2, 2022

• Full Guideline

Thursday, February 24, 2022

• Full Guideline

Tuesday, February 1, 2022

• Full Guideline

Wednesday, January 19, 2022

• Full Guideline
• Statement on Therapies for High-Risk, Nonhospitalized Patients

Wednesday, January 5, 2022

• Full Guideline
• Statement on Anticoagulation in Hospitalized Patients
• Statement on Evusheld for PrEP

Thursday, December 30, 2021

• Full Guideline
• Statement on Paxlovid Drug-Drug Interactions

Thursday, December 23, 2021

• Full Guideline
• Statement on Anti-SARS-CoV-2 mAbs and RDV and Omicron
• Statement on Patient Prioritization for Outpatient Therapies

Thursday, December 16, 2021

• Full Guideline

Wednesday, October 27, 2021

• Full Guideline

Tuesday, October 19, 2021

• Full Guideline

Thursday, October 7, 2021

• Full Guideline
• Updated Statement on the Prioritization of Anti-SARS-CoV-2 mAbs

Wednesday, September 29, 2021

• Full Guideline
• Statement on Bamlanivimab Plus Etesevimab as PEP

Wednesday, September 15, 2021

• Full Guideline
• Statement on Bamlanivimab Plus Etesevimab for the Treatment of Mild to Moderate COVID-19

Friday, September 3, 2021

• Full Guideline
• Statement on Monoclonal Antibodies When There Are Logistical Constraints

Wednesday, August 25, 2021

• Full Guideline

Wednesday, August 18, 2021

• Statement on Casirivimab plus Imdevimab as PEP

Tuesday, August 17, 2021

• Full Guideline

Wednesday, August 4, 2021

• Full Guideline

Thursday, July 8, 2021

• Full Guideline
• Statement on Monoclonal Antibodies

Thursday, June 17, 2021

• Full Guideline
• Statement on Casirivimab Plus Imdevimab

Friday, June 11, 2021

• Full Guideline

Thursday, May 27, 2021

• Full Guideline
• Statement on Baricitinib EUA

Wednesday, April 21, 2021

• Full Guideline

Thursday, April 8, 2021

• Full Guideline
• Statement on Anti-SARS-CoV-2 Monoclonal Antibodies EUA

Friday, March 5, 2021

• Full Guideline
• Updated Statement on Tocilizumab

Tuesday, March 2, 2021

• Full Guideline
• Statement on Bamlanivimab Plus Etesevimab Combination

Thursday, February 11, 2021

• Full Guideline

Wednesday, February 3, 2021

• Full Guideline
• Statement on Tocilizumab (and Other IL-6 Inhibitors)

Thursday, January 14, 2021

• Full Guideline
• Statement on Ivermectin

Thursday, December 17, 2020

• Full Guideline

Monday, December 14, 2020

• Full Guideline
• Statement on Baricitinib EUA

Thursday, December 3, 2020

• Full Guideline

Wednesday, December 2, 2020

• Full Guideline
• Statement on Casirivimab Plus Imdevimab EUA

Wednesday, November 18, 2020

• Full Guideline
• Statement on Bamlanivimab EUA

Tuesday, November 3, 2020

• Full Guideline

Thursday, October 22, 2020

• Full Guideline

Friday, October 9, 2020

• Full Guideline

Tuesday, September 1, 2020

• Full Guideline
• Statement on Convalescent Plasma EUA

Thursday, August 27, 2020

• Full Guideline

Thursday, July 30, 2020

• Full Guideline

Friday, July 24, 2020

• Full Guideline

Friday, July 17, 2020

• Full Guideline

Thursday, June 25, 2020

• Full Guideline
• Recommendations for Dexamethasone in Patients with COVID-19

Tuesday, June 16, 2020

• Full Guideline

Thursday, June 11, 2020

• Full Guideline

Tuesday, May 12, 2020

• Full Guideline

Tuesday, April 21, 2020

• Full Guideline